Trending...
- RYFF AND SIMON COWELL-BACKED LOUNGES.TV COLLABORATE TO CONNECT CREATORS TO BRANDS IN THE UK
- ** Introducing *Smart Phone* – A YA Mystery Adventure from the Mysterious Josh Eber **
- Holman United Methodist Church to Host Post-Election Debrief
SAN JOSE, Calif. - Californer -- Biomed Industries, Inc. (Biomed) announced today that it has developed a promising obesity drug, NA-921, which is poised for Phase 2/3 clinical trials. NA-921 is a small molecule drug available in oral formulation.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
The Company is in discussions with potential partners for collaboration on a Phase 3 trial of NA-921, a promising candidate for treatment of diabetic obesity.
The drug is a once-a-day oral capsule based on a novel mechanism of action of GLP-1 and IGF-1 for which the Company has recently filed for patent protection. Its analogue/prodrug has already been approved by the FDA for a certain rare disease, for which the Company is in separate licensing discussions.
"We are actively seeking collaborators to work with us on this exciting new approach for the treatment of Diabetes and Obesity. NA-921 is novel in its approach to targeting both GLP-1 and IGF-1. The drug has shown only minor adverse events in a Phase 2A trial", said Dr, Lloyd Tran, Chairman and CEO of Biomed Industries. He continued "We believe that this new approach will provide a clear choice for patients wanting to have a much more convenient way to take an obesity drug as well as minimize side-effects they experience with current treatments."
More on The Californer
- MAX INVESTIGATION NOTICE: Investigation Launched into MediaAlpha, Inc. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
- California: CHP arrests 64 suspects in first two weeks of San Bernardino surge operation
- Moorpark College Named 2024 Neighborhood Champion Recipient
- New Book Release: The Focused Faith by Dr. Brian S. Bovee – A Timely Guide to Reclaiming Focus
- Mahershala Ali to Receive the Muhammad Ali Voice of Humanity Honor from the Society of Voice Arts and Sciences, Underwritten by Audible
About Biomed Industries, Inc.
Biomed Industries™, Inc. is a pioneering bio-pharmaceutical enterprise dedicated to the innovation, development, and commercialization of groundbreaking drug therapeutics addressing unmet medical needs. Biomed stands at the forefront of discovery with its new portfolio of clinical stage drugs targeting Alzheimer's disease, MDD, Rett Syndrome, other neurological challenges, and now Diabetes/Obesity. Additionally, the company is venturing into harnessing AI for drug discovery, enhancing clinical trial procedures, and various other critical domains within the pharmaceutical and medical device sectors.
For further details, please visit https://www.biomedind.com.
Source: Biomed Industries Inc.
Filed Under: Medical
0 Comments
Latest on The Californer
- Bell Textron Selects Integris Composites as Armor Supplier for U.S. Army's Future Long Range Assault Aircraft (FLRAA)
- Guitar Pickup Guru David Shepherd Launches His Own Boutique Brand
- BKM Capital Partners Proudly Celebrates its 100-Employee Milestone
- Developers Highlight Code Examples as the Top Need in AI Development
- Breaking Entertainment News WOW Creations Media To Host Golden Globes Celebrity Gifting Event
- Primary Point of Impact Contributing to Differences in Claims Severity for Battery Electric and Internal Combustion Engine Vehicles
- Kamoti Launches "The Hammock" Merchandise Store with Conservation-Focused limited Edition Hoodie
- FUELD Conference To Address The Future Of E-Commerce In Its 2024 & 2025 Editions
- Taiwan Design Research Institute (TDRI) Highlights Global Collaborations at San Diego World Design Capital Forum
- Debuting at number one, the new album Contributions of Songs
- Radical new patented device turns any monitor into a broadcast studio
- Snell & Wilmer Enters Into New Lease in Orange County to Accommodate Expansion
- Have Breakfast with Santa And Shop For Christmas Trees At Simi Valley Family YMCA - December 7
- Talcada Launches Innovative Drug Testing Services, Expanding Accessibility & Convenience
- Cal State LA president elected to board of the Coalition of Urban and Metropolitan Universities
- McClure Films Announces 2nd Unit Preliminary Filming for "EthanAlmighty - the Movie," December 5
- B Corp Certified PPE Supplier Gains 5th Certification
- A Military Family Asks for CalPERS Accountability As The Country Says "Thank You For Your Service"
- Breaking Celebrity News Actor/Influencer Andre Swilley To Attend Tiana's Bayou Adventure Opening
- BK Flooring Services Launches New Website